Nuvalent, Inc. (NUVL) is a pre-commercial-stage oncology company with no product revenue as of the March 31, 2026 10-Q period end. Under a liquidation lens, the recovery posture is modestly positive on a gross asset basis but is driven almost entirely by liquid financial assets. Total assets of $1.33B are dominated by current assets of $1.31B, of which $1.13B are marketable securities (AFS debt securities) and $159.7M is cash and cash equivalents. Applying standard liquidation haircuts: cash at 100% contributes ~$160M; AFS securities at 95-100% (high-quality short-duration instruments typical for clinical-stage biotechs) contribute ~$1.07-1.13B; prepaid and other current assets of ~$20.5M at 25-40% contribute ~$5-8M. Noncurrent assets of $23.2M (likely operating lease ROU assets and deposits) carry minimal liquidation value at 20-30%, contributing ~$5-7M. All intangibles and IP embedded in the R&D platform carry zero liquidation value. Gross liquidation proceeds approximate $1.24-1.30B. On the liability side, total liabilities of $156.8M are carried at face value. Current liabilities of $81.1M include accounts payable of $22.1M, accrued liabilities of $58.9M (inclusive of employee-related accruals of $8.2M), and the residual in other current items. Non-current liabilities are de minimis at $0 per OtherLiabilitiesNoncurrent; however, operating lease obligations are likely embedded in a non-current liability line not separately tagged in XBRL — this is discussed in the filing narrative but does not surface as a distinct XBRL tag. Filing discusses a Cambridge, MA office lease but does not separately tag operating lease liability in XBRL. Equity recovery to common is therefore approximately $1.08-1.14B on a liquidation basis against book stockholders' equity of $1.17B, a modest haircut driven by non-cash asset impairments (AFS unrealized losses of $2.1M, prepaid write-downs) and the zero-value treatment of intangibles. The accumulated deficit stands at $1.08B. The company reported a net loss of $109.3M for Q1 2026 and operating cash outflows of $92.4M, consistent with a pre-revenue clinical-stage burn rate. Cash position decreased by $102M in the quarter. With approximately $1.29B in combined cash and marketable securities, the company maintains substantial runway, but the liquidation cushion narrows each quarter at the current burn pace. No debt obligations are present in the capital structure.
▼ Community Notes